Drägerwerk AG & Co. KGaA/€DRW8
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA is a German company specializing in medical and safety technology. The company provides a range of products and solutions in the fields of critical care, which includes anesthesia workstations, ventilators, and patient monitoring, as well as safety products for personal protection, gas detection, and firefighting. Dräger was founded in 1889 and is headquartered in Lübeck, Germany. Its operations extend globally, serving various industries such as healthcare, emergency services, mining, and industrial applications. Drägerwerk's strategic strength lies in its focus on high-quality, technologically advanced products and its long-standing expertise in medical and safety technologies.
- Ticker
- €DRW8
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 16,009
- Headquarters
- Lübeck, Germany
- Website
- www.draeger.com
DRW8 Metrics
BasicAdvanced
€1.9B
8.87
€9.13
0.63
€2.21
2.73%
Price and volume
Market cap
€1.9B
Beta
0.63
52-week high
€88.20
52-week low
€56.40
Average daily volume
3.2K
Dividend rate
€2.21
Financial strength
Current ratio
2.051
Quick ratio
1.167
Long term debt to equity
0.186
Total debt to equity
0.234
Dividend payout ratio (TTM)
24.51%
Interest coverage (TTM)
12.43%
Profitability
EBITDA (TTM)
311.657
Gross margin (TTM)
45.74%
Net profit margin (TTM)
4.79%
Operating margin (TTM)
7.11%
Effective tax rate (TTM)
34.22%
Revenue per employee (TTM)
€220,000
Management effectiveness
Return on assets (TTM)
5.15%
Return on equity (TTM)
10.93%
Valuation
Price to earnings (TTM)
8.872
Price to revenue (TTM)
0.425
Price to book
1.15
Price to tangible book (TTM)
1.44
Price to free cash flow (TTM)
8.609
Free cash flow yield (TTM)
11.62%
Free cash flow per share (TTM)
9.408
Dividend yield (TTM)
2.73%
Forward dividend yield
2.73%
Growth
Revenue change (TTM)
6.37%
Earnings per share change (TTM)
71.51%
3-year revenue growth (CAGR)
2.96%
10-year revenue growth (CAGR)
3.47%
3-year earnings per share growth (CAGR)
61.03%
10-year earnings per share growth (CAGR)
25.53%
3-year dividend per share growth (CAGR)
128.61%
10-year dividend per share growth (CAGR)
28.15%
Bulls say / Bears say
Safety demand is accelerating: third-quarter order intake in the division rose 20.2%, lifting its nine-month increase to 13.1%. That gives Dräger a stronger order pipeline in a business currently driving growth. (EQS News)
First-half sales grew 7.7% and EBIT more than trebled to €64 million as the gross margin improved and expenses grew more slowly than sales. The EBIT figure included a €7.8 million customs refund, but the operating progress still points to a recovery. (EQS News)
The FDA cleared Dräger’s IACS VG8.1 patient-monitoring system and lifted its 2020 warning letter, removing remaining US marketing restrictions on the monitoring portfolio. This could support renewed customer wins and portfolio sales, although the benefit is expected to build over time. (Finanznachrichten.de)
Third-quarter EBIT fell to €48 million from €56.7 million and the margin narrowed to 5.6% from 6.8%, despite €20.1 million of customs refunds in the quarter. That raises doubts about the strength of underlying earnings and the pace of margin recovery. (EQS News)
Medical remains a weak spot: third-quarter sales fell 1.4% and orders fell 3.0% year on year, while nine-month medical order intake was down 3.5%. Continued weakness here could limit growth beyond the stronger safety division. (EQS News)
Higher personnel and freight costs are adding pressure, and management said Middle East-related freight increases could cost up to €10 million in 2026. These expenses may eat into the benefit from sales growth and better gross margins. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
DRW8 Financial Performance
Revenues and expenses
DRW8 Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.